[1] 陈万青, 郑荣寿. 中国女性乳腺癌发病死亡和生存状况[J]. 中国肿瘤临床, 2015, 42(13):668-674.
[2] Mori M, Akashi-Tanaka S, Suzuki S, et al. Diagnostic accuracy of contrast-enhanced spectral mammography in comparison to conventional full-field digital mammography in a population of women with dense breasts[J]. Breast Cancer, 2017, 24(1):104-110.
[3] Chaiwerawattana A, Thanasitthichai S, Boonlikit S, et al. Clinical outcome of breast cancer BI-RADS 4 lesions during 2003-2008 in the National Cancer Institute Thailand[J]. Asian Pacific Journal of Cancer Prevention, 2012, 13(8):4063.
[4] Yoon J H, Kim M J, Moon H J, et al. Subcategorization of ultrasonographic BI-RADS category 4:positive predictive value and clinical factors affecting it[J]. Ultrasound in Medicine & Biology, 2011, 37(5):693-699.
[5] Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013[J]. Cancer Letter, 2017, 401:63-71.
[6] Seibert J A. The Essential Physics of Medical Imaging[M]. Philadelphia:Lippincott Williams & Wilkins, 2013.
[7] Bhimani C, Li L, Liao L, et al. Contrast-enhanced spectral mammography:modality-specific artifacts and other factors which may interfere with image quality[J]. Academic Radio-logy, 2017, 24(1):89-94.
[8] Patel B K, Lobbes M B I, Lewin J, et al. Contrast enhanced spectral mammography:a review[J]. Seminars in Ultrasound CT and MRI, 2018, 39(1):70-79.
[9] Cheung Y C, Juan Y H, Lin Y C, et al. Dual-energy contrast-enhanced spectral mammography:enhancement analysis on BI-RADS 4 non-mass microcalcifications in screened women[J]. Plos One, 2016, 11(9):e0162740.
[10] Cheung Y C, Lin Y C, Wan Y L, et al.Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone:interobserver blind-reading analysis[J]. Europe Radiology, 2014, 24(10):2394-2403.
[11] ?uczyńska E, Heinze-Paluchowska S, Hendrick E, et al. Comparison between breast MRI and contrast-enhanced spectral mammography[J]. Medical Science Monitort, 2015, 21:1358-1367.
[12] Rudnicki W, Heinze S, Niemiec J, et al. Correlation between quantitative assessment of contrast enhancement in contrast-enhanced spectral mammography (CESM) and histopathology-preliminary results[J]. Europe Radiology, 2019, 29(11):6220-6226.
[13] Badr S, Laurent N, Régis C, et al. Dual-energy contrast-enhanced digital mammography in routine clinical practice in 2013[J]. Diagnostic and Interventional Imaging, 2014, 95(3):245-258.
[14] Patel B K, Hilal T, Covington M, et al. Contrast-enhanced spectral mammography is comparable to mri in the assessment of residual breast cancer following neoadjuvant systemic therapy[J]. Annals of Surgical Oncologyl, 2018, 25(5):1350-1356.
[15] 姜婷婷, 张盛箭, 李瑞敏, 等. 对比增强能谱X线摄影对乳腺疾病的诊断价值[J]. 中华放射学杂志, 2017, 51(4):273-278.
[16] Bhimani C, Matta D, Roth R G, et al. Contrast-enhanced spectral mammography:technique, indications, and clinical applications[J]. Academic Radiology, 2016, 24(1):84.
[17] Vera F, Felix D, Diane M, et al. Correlation of contrast agent kinetics between iodinated contrast-enhanced spectral tomosynthesis and gadolinium-enhanced MRI of breast lesions[J]. European Radiology, 2013, 23(6):1528-1536. |